DUPIXENT specifically targets a source of underlying inflammation in AD1
IL-4 and IL-13 are important in the development of Type 2 inflammation and its downstream effects1
DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injecton1
Learn more about how DUPIXENT works
-
DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–4
Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131-4Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41
Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131
-
DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–4
Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131-4Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41
Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131
DUPIXENT is a targeted immunomodulator unlike broad spectrum immunosuppressants1
Request a representative call
Have a question about DUPIXENT?
Get answers from a representative.
Find out more
Inflammatory pathways
What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.
Find out more
- DUPIXENT Summary of Product Characteristics. September 2021.
- Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155–172.
- Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
- D’Erme A, et al. Drug Des Devel Ther. 2017;11:1473–1480.
- McCormick M, et al. Cytokine. 2015;75(1):38–50.
AD, atopic dermatitis; γC, gamma C subunit; IL, interleukin; IL-4Rα; Interleukin 4 receptor alpha; IL-13Rα1, interleukin 13 receptor alpha 1; ILC, innate lymphoid cells; JAK, Janus kinase;
Th, T-helper cells; TYK2, tyrosine kinase 2.
References
MAT-IE-2101040(v4.0) | Date of preparation: February 2022
